An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease by Singh, Sonal & Loke, Yoon K
© 2010 Singh and Loke, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Chronic Obstructive Pulmonary Disease 2010:5 189–195
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
189
RevIew
open access to scientific and medical research
Open Access Full Text Article
6942
An overview of the benefits and drawbacks  
of inhaled corticosteroids in chronic  
obstructive pulmonary disease
Sonal Singh1 
Yoon K Loke2
1Department of Medicine, Johns 
Hopkins University School of 
Medicine, Baltimore, Maryland, USA; 
2School of Medicine, Health Policy 
and Practice, University of east Anglia, 
Norwich, england
Correspondence: Sonal Singh 
Department of Medicine, Johns  
Hopkins University School of  
Medicine, 1830 e Monument St, Suite 
8063, Baltimore, MD, 21287, USA 
Tel +1 410 955 9869 
Fax +1 410 955 0825 
email ssingh31@jhu.edu
Background: The benefit harm profile of inhaled corticosteroids, and their effect on patient 
oriented outcomes and comorbid pneumonia, osteoporosis and cardiovascular disease in patients 
with chronic obstructive pulmonary disease remain uncertain.
Methods: An overview of the evidence on the risks and benefits of inhaled corticosteroids 
(fluticasone and budesonide) in chronic obstructive pulmonary disease from recent random-
ized controlled trials and systematic reviews. Observational studies on adverse effects were 
also evaluated.
Results: Evidence from recent meta-analysis suggests a modest benefit from inhaled 
  corticosteroid long-acting beta-agonist combination inhalers on the frequency of exacerba-
tions, (rate ratio [RR], 0.82; 95% confidence interval [CI]: 0.78 to 0.88), in improvements 
in quality of life measures, and forced expiratory volume in one second when compared to 
long-acting beta-agonists alone. On the outcome of pneumonia, our updated meta-analysis of 
trials (n = 24 trials; RR, 1.56; 95% CI: 1.40–1.74, P , 0.0001) and observational studies (n = 4 
studies; RR, 1.44; 95% CI: 1.20–1.75, P = 0.0001) shows a significant increase in the risk of 
pneumonia with the inhaled corticosteroids currently available (fluticasone and budesonide). 
Evidence for any intraclass differences in the risk of pneumonia between currently available 
  formulations is inconclusive due to the absence of head to head trials. Inhaled corticosteroids 
have no   cardiovascular effects.
Conclusions: Among patients with chronic obstructive pulmonary disease, clinicians should 
carefully balance these long-term risks of inhaled corticosteroid against their symptomatic 
benefits.
Keywords: inhaled corticosteroids, chronic obstructive pulmonary disease, pneumonia, 
  cardiovascular events
Introduction
Inhaled corticosteroids (ICS) are widely used for the treatment of chronic   obstructive 
pulmonary disease (COPD). They are mainly indicated in combination with a 
long-acting beta-agonist (LABA) according to the current guidelines in patients 
with severe COPD and recurrent exacerbations (.3) to decrease the frequency of 
  exacerbations.1 The ICS currently available include inhaled fluticasone, inhaled budes-
onide, and inhaled mometasone, however, none of these are approved for single agent 
use (ie, without the LABA) in COPD.
ICS are the preferred agents for treatment of asthma. However, the role of ICS 
in COPD is uncertain. The debate over their optimal role has further intensified with International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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the recent publication of several studies suggesting only 
modest benefit and potential harm.2–4
COPD is characterized by a progressive decline in lung 
function. Additional features such as bronchial hyperre-
sponsiveness and reversibility together with neutrophilic 
inflammation play an important role in COPD.5,6 ICS have 
been evaluated in several long-term randomized controlled 
trials (RCTs; usually in combination with a LABA) in the 
treatment of COPD.7–11 
Patients with COPD are at risk from underlying comor-
bidities such as cardiovascular disease,12 pneumonia,13,14 
and osteoporosis.15 The potential impact of ICS on these 
comorbidities in patients with COPD needs careful evalua-
tion. Our objective is to critically review the evidence on the 
benefits of long-term ICS use on patient oriented outcomes 
(exacerbations, health-related quality of life), along with 
their risks in COPD.
Methods
On completion of our previous systematic review in 2008,4 
we set up automated weekly electronic updates from PubMed 
for trial reports of ICS in COPD to update our assessment of 
any potential adverse effects. For additional outcomes (such 
as evidence of beneficial effects), we evaluated Cochrane 
systematic reviews and meta-analysis of RCTs that had been 
retrieved in our previous searches. We used an intention to 
treat analysis (all participants analyzed within their random-
ized intervention group) to update our previous findings 
on the adverse effects of ICS therapy, based on data in the 
peer-reviewed publications, and manufacturer’s data (for 
any outcomes that were not fully reported in the published 
manuscripts).4,16–18 Full details of our search strategy and 
methods of meta-analysis on the adverse effects have been 
published elsewhere.4,16–18
ICS are only indicated in combination with LABAs in 
COPD. Hence, we evaluated the evidence on the beneficial 
effect of this comparison against LABAs alone, in RCTs. For 
the assessment of adverse effects however, we evaluated two 
separate comparisons: (i) corticosteroid/LABA combination 
versus LABAs, and (ii) ICS versus placebo. For previously 
unrecognized adverse effects such as pneumonia, the com-
parison against placebo provides a clearer insight into the 
causative agent, which may not be easily apparent in active 
comparator trials. The evaluation of the combination of ICS 
and LABAs against placebo does not inform whether any 
new adverse effects stemmed from the ICS alone, or from a 
drug interaction with concomitant LABA. We also evaluated 
the consistency of the evidence on adverse effects from 
observational studies.
Results
Benefits on FEV1, frequency  
of exacerbations, and quality of life
In contrast to LABAs, the combination of ICS and LABA 
have been postulated to decrease the   frequency of exacer-
bations, the number of people experiencing exacerbations, 
improve post-dose forced expiratory volume in one second 
(FEV1), and statistically significant improvements in health 
related quality of life.
The evidence suggests that ICS in combination with a 
LABA appear to modestly reduce the risk of exacerbations, 
when compared to LABAs, by approximately 20%–25% 
based on evidence from systematic reviews and meta-analysis 
of RCTs.19–24
A Cochrane review of ten trials among participants with 
severe COPD reported a modest decrease in exacerbation 
rates with combined inhalers (rate ratio [RR] 0.82; 95% 
confidence interval [CI]: 0.78 to 0.88), and improvements 
in quality of life measures and FEV1 compared to LABAs 
alone.19 Another recent meta-analysis from eighteen RCTs 
reported a similar relative risk reduction in exacerbations. 
In comparison to LABAs alone, combined ICS and LABA 
reduced the number of moderate exacer  bations (RR, 0.84; 
95% CI: 0.74 to 0.96) and provided statistically significant 
reductions in the St George Respira  tory Questionnaire 
(SGRQ) total score (weighted mean   difference, -1.88; 95% 
CI: -2.44 to -1.33) and FEV1.21 Assuming a baseline event 
rate of 0.97 exacerbations per year, for exacerbations in 
adult patients with COPD, similar to the placebo event rate 
in the trial population of the TORCH study, a meta-analysis 
reported an annualized Number Needed to Treat (NTT) of 
6 for exacerbations for ICS when added to LABAs.23
However, a network meta-analysis which combined 
both direct and indirect evidence from 35 RCTs reported no 
significant difference between ICS combination on exacer-
bations (odds ratio [OR], 0.93; 95% CI: 0.84 to 1.04), when 
compared to LABAs.22
ICS added to LABA, as compared to LABAs alone, have 
not been conclusively shown to demonstrate clinically sig-
nificant improvement in measures of health-related   quality 
of life (a decrement of 4 points on the SGRQ   questionnaire), 
exacerbations requiring hospitalizations or overall   mortality.11 
In the absence of individual patient data, it is not pos-
sible to determine if there may be certain subgroups of International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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participants where there is a more pronounced beneficial 
effect (.4 points of the SGRQ).
There was no significant effect of ICS combinations 
on mortality,19,21 and lack of significant improvements in 
severe exacerbations (RR, 0.91; 95% CI: 0.82 to 1.01).21 In 
another meta-analysis reported that the combination of ICS 
and LABAs reduced mortality when compared to placebo.20 
However, trials that have shown benefit are limited by the 
inappropriate statistical analysis of exacerbation rates, com-
paring patients withdrawing from ICS and not conducting 
appropriate factorial analysis for 2 × 2 trials.25 The interpreta-
tion of evidence on the benefit of ICS is complicated by the 
high dropout rate of nearly 30%–40% in COPD trials, and 
the lack of intention to treat analysis.
Long-term inhaled corticosteroid use  
and the risk of pneumonia: a class effect
In early 2009, we reported an approximate 60% increase 
in the risk of pneumonia (RR 1.60; 95% CI: 1.33–1.92, 
P , 0.001) with the currently available ICS for COPD (flu-
ticasone and budesonide), without an increase in pneumonia 
related mortality or overall mortality in a multidrug meta-
analysis of the class of ICS in COPD.4 The limitation of our 
analysis was the lack of published data on budesonide, with 
only two budesonide trials included in the meta-analysis.
The paucity of data on budesonide was addressed by 
the subsequent publication of an industry supported pooled 
analysis on the risk of pneumonia in 7 budesonide trials 
which reported a small, though nonstatistically significant 
excess risk of pneumonia with inhaled budesonide.26 The 
analysis was censored at 1 year despite the availability of 
data extending up to three years, and included potentially 
ineligible trials and comparators.17 Our re-analysis of the 
budesonide dataset, addressing these limitations has been 
published elsewhere.17
Our updated intention to treat the meta-analysis of 
24 RCTs of the available ICS (n = 16 fluticasone trials, 
7 budesonide trials and one mometasone trial) on pneumo-
nia, reported throughout the duration of the trials shows a 
significantly increased risk of pneumonia within the class 
of ICS (RR, 1.56; 95% CI: 1.40–1.74, P , 0.0001) simi-
lar to our previous analysis.4,17 Assuming a baseline event 
rate of 30 per 1000 person-years for serious pneumonia in 
adult patients with COPD, similar to the control event rate 
in the trial population of the TORCH study, the annualized 
  Number Needed to Harm for pneumonia associated with ICS 
use is estimated to be at 60 (95% CI, 44–84). The elevated 
risk remains consistent, irrespective of whether ICS added 
to LABA (ICS-LABA) was compared to LABA or ICS to 
placebo. The addition of the recent budesonide data did not 
change the size and direction of the pooled estimate. Despite 
the large number of trials, and the inclusion of three differ-
ent types of ICS, overall heterogeneity was low, raising the 
possibility of a class effect.
In comparison to fluticasone (16 RCTs), the safety data-
base of inhaled budesonide remains heterogenous, and lim-
ited to only seven RCTs and total sample size of nearly 40% 
of fluticasone. The relatively low proportion of pneumonia 
events in the budesonide trials of ≈ 3.5% in budesonide versus 
≈ 6.2% in fluticasone trials reflects the under ascertainment 
of pneumonia, and shorter duration of inhaled budesonide 
exposure, which reduced the power of the budesonide analy-
sis to detect any significant increase in risk of pneumonia. 
In subgroup analysis, focusing on budesonide exposure, the 
direction of effect with budesonide was consistent with an 
increased risk of pneumonia; however, this does not meet 
the threshold for statistical significance (Figure 1A). Such 
subgroup analysis for intraclass differences should only be 
interpreted for their direction of effect.
Substantial heterogeneity was seen in the meta-analysis 
of budesonide versus placebo, due to presence of two trials 
with opposing findings – exclusion of either trials elimi-
nated the statistical heterogeneity.7,8 One budesonide trial 
which had a relatively long exposure period (1500 patient 
years – almost twice as long as the other trials), reported a 
significant doubling in the risk of pneumonia with inhaled 
budesonide (RR 2.09; CI: 1.16–3.76) (Figure 1B).7 In 
contrast, the lowest risk estimate for pneumonia (RR 0.67; 
95% CI: 0.37–1.20) stemmed from a trial by Vestbo and 
colleagues that recruited patients with the mildest severity 
of COPD and the highest FEV1 of ≈ 80%.8 The authors of 
the earlier meta-analysis state that “All trials fulfilled our 
inclusion criteria, except for Vestbo and colleagues’study, 
which did not include the criterion, that patients had to 
have at least 10 pack-years smoking history”.26 Sensitivity 
analysis excluding this study shows a statistically signifi-
cantly increased risk of pneumonia with inhaled budesonide 
(RR, 1.36; 95% CI: 1.02–1.81, P = 0.04). (Figure 1B)
The presence of substantial heterogeneity signifies that 
we cannot rule out the possibility that pneumonia is a class 
effect of ICS use. It is difficult to draw any reliable conclu-
sions on any intraclass differences between fluticasone and 
budesonide given the paucity of head to head comparisons. 
Any possible differences in the magnitude of the risk of International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Figure 1A Intention to treat meta-analysis of budesonide and the risk of pneumonia in RCTs of COPD (any severity).  
Abbreviations: COPD, chronic obstructive pulmonary disease; RCT, randomized clinical trial; CI, confidence interval.
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Figure 1B Sensitivity analysis of budesonide and the risk of pneumonia with exclusion of study in mild COPD.  
Abbreviations: COPD, chronic obstructive pulmonary disease; RCT, randomized clinical trial; CI, confidence interval.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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pneumonia between fluticasone and budesonide may relate 
to the weaker potency of inhaled budesonide.26
None of these trials were designed to assess the risk of 
pneumonia and it is unclear if radiographic confirmation was 
available. However, the increased risk of ‘serious’ pneumonia 
(reported as hospitalization, disability or death) increases the 
robustness of our analysis.17 The results of additional reviews 
are also consistent with the overall evidence confirming a 
significantly increased risk of pneumonia with ICS.19,23,24
Four observational studies of ICS on the risk of pneumo-
nia in COPD are available.27–30 An approximate 70% relative 
risk increase, in the risk of hospitalization for pneumonia 
was reported in a population based case-control study from 
Canada among ICS users in elderly COPD patients compared 
to nonusers.27 Another study in the Veterans Affairs data-
base confirmed an increased risk of pneumonia with ICS.28 
Two unpublished observational studies reported on the risk 
of pneumonia with ICS exposure in the General Practice 
Research Database.29,30 These studies reported exposure to 
all ICSs (including budesonide), although the proportions of 
patients on each individual agents are unknown. A meta-anal-
ysis of the four observational studies shows a significantly 
increased risk of pneumonia with ICS (RR, 1.44 95% CI: 
1.20 –1.75, P , 0.0001) consistent with the evidence from 
other trials (Figure 2).The limitations of these studies include 
the possibility of residual confounding, lack of lung function 
data, and reliance on dispensing records.
The precise biological mechanism underlying such an 
increased risk of pneumonia with ICS, and any within-
class differences in risk, are uncertain. Patients aged above 
55 years, with severe COPD and FEV1 , 50%, with a recent 
history of exacerbations, and those with worse dyspnea 
scores and lower body mass indexes appear to be at the 
highest risk of ICS associated pneumonia.31 The trials sug-
gest that the increased risk of pneumonia with ICSs are not 
associated with an increase in pneumonia-related mortality 
or overall mortality, whereas observational studies which 
included   different study populations reported an increase in 
pneumonia-related mortality.27
Long-term inhaled corticosteroid use  
and effect of cardiovascular outcomes
ICS modulates inflammation and were thought to potentially 
reduce cardiovascular outcomes and mortality in observa-
tional studies.16 The evidence of cardiovascular benefit in 
observational studies was contradicted by our robust meta-
analysis of 23 RCTs which demonstrated no effect of ICS 
on myocardial infarction (RR, 0.95; 95% CI: 0.73–1.23, 
P = 0.68), cardiovascular death (RR, 1.02; 95% CI, 0.81–1.27, 
P = 0.89, I2 = 0%), or mortality (RR, 0.96; 95% CI: 0.86–1.07, 
P = 0.43) in COPD. There was the presence of significant 
publication bias in the positive findings from previous obser-
vational studies, along with residual confounding inherent 
in epidemiological studies.16 Thus, ICSs appear to have no 
effect on cardiovascular outcomes in COPD.
effect of ICS on osteoporosis
A systematic review and meta-analysis which included 
observational studies among older adults with COPD and 
asthma found no evidence of an increased fracture risk 
except among those who used high doses of ICS.32 A previous 
meta-analysis of RCTs that reported no increased risk of frac-
tures was limited to 4 trials.32 Several observational studies 
have reported an increased fracture risk with ICS although the 
evidence is conflicting.32–36 However; observational studies 
are susceptible to confounding by disease severity or higher 
doses of ICS.37 Observational evidence indicates a decline in 
bone mineral density with ICS use in premenopausal women 
with asthma.37 However, analysis from Towards a Revolution 
in COPD Health (TORCH) reported no significant effect of 
inhaled fluticasone on bone.38 Adequately powered RCTs 
that determine the risk of fractures with ICS have not been 
conducted, especially among postmenopausal women with 
osteoporosis.
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Figure 2 Meta-analysis of inhaled corticosteroids and the risk of pneumonia in observational studies of COPD.  
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, confidence interval.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Cataracts
Observational studies consistently indicate a modest risk of 
cataracts, attributable largely to high dosage and long dura-
tion of ICS use, consistent with the systemic absorption of 
ICS.39 Although not specific to COPD, a meta-analysis of ICS 
use in adult patients reported a number needed to harm of 
16 [95% CI, 13–19] with ICS use based on a meta-analysis 
of epidemiological studies.40
Research priorities
Appropriate factorial analysis of RCTs accounting for the 
withdrawal of ICS use is needed to determine the true benefit 
of ICS use. Further research is needed to identify the best 
way to measure health related quality of life in patients with 
COPD, as there may be a subset of patients who benefit from 
ICS in COPD. Robust evidence needs to be generated from 
adequately powered long term trials to determine if COPD 
patients with an asthmatic component may derive the great-
est benefit from ICS.
Head-to-head long-term trials comparing inhaled flutica-
sone to budesonide with objective radiographic pneumonia 
definitions are needed to ascertain any intraclass differences 
in the risk of pneumonia. These studies should be adequately 
powered to determine whether pneumonia associated with 
ICS is truly benign and also identify the specific etiologic 
agents via microbiologic confirmation. Prospective studies 
should determine whether the use of antibiotics or specific 
delivery systems may ameliorate this risk. Adequately 
powered head to head trials which compare fluticasone to 
budesonide, each in combination with a LABA, and ascertain 
cardiovascular outcomes are also needed in COPD.
The absence of conclusive evidence on the harm of 
fractures from inadequately powered trials should not be 
construed as proof of safety. Manufacturers of ICSs need to 
make data from RCTs, available to independent investiga-
tors to conduct appropriate intention to treat analysis on any 
adverse effects without censoring participants.
Overall risk benefit assessment
The risk benefit profile of ICS should not be considered in 
isolation, it should consider the risks and benefits of available 
alternatives. Therapeutic options for patients with COPD 
are limited although they include LABAs and the class of 
inhaled anticholinergics. Both LABAs and anticholinergics 
decrease exacerbations; however, they have been linked to 
  cardiovascular safety concerns.41–45 No single therapeutic 
agent has been conclusively shown to reduce mortality 
in patients with COPD in any clinical trial.11,46 Clinicians 
should balance the modest benefit on exacerbations when 
ICSs are added to a LABA against their long term risks of 
pneumonia.
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